Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance
Levesque, S.; Carleton, G.; Duque, V.; Goupil, C.; Fiset, J.-P.; Villeneuve, S.; Normandeau, E.; Morin, G.; Dumont, N.; Nelson, B. H.; Laganiere, J.; Boyle, B.; Lum, J. J.; Doyon, Y.
Show abstract
Chimeric antigen receptors (CARs) reprogram T cells to recognize and target cancer cells. Despite remarkable responses observed with CAR-T cell therapy in patients with hematological malignancies, CAR-T cell engineering still relies mostly on randomly integrating vectors, limiting the possibilities of fine-tuning T cell function. Here, we designed a CRISPR-based marker-free selection strategy to simultaneously target a therapeutic transgene and a gain-of-function mutation to the MTOR locus to enrich cells resistant to rapamycin, a clinically used immunosuppressant. We readily engineered rapamycin-resistant (RapaR) CAR-T cells by targeting CAR expression cassettes to the MTOR locus. Using in vitro cytotoxicity assays, and a humanized mouse model of acute lymphoblastic leukemia, we show that RapaR-CAR-T cells can efficiently target CD19+ leukemia cells in presence of immunosuppressing doses of rapamycin. Furthermore, our strategy allows multiplexed targeting of rapamycin-regulated immunoreceptors complexes (DARICs) to the MTOR and TRAC loci to pharmacologically control CAR-T cells activity. We foresee that our approach could both facilitate the enrichment of CRISPR-engineered CAR-T cells ex vivo and in vivo while improving tumor eradication.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer 96%
- A single cell atlas reveals distinct immune landscapes in transplant and primary tumors that determine response or resistance to immunotherapy 96%
- Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy 96%
Similar papers in this journal
- Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 95%
- Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in mediating targeted therapy dosage challenges 95%
- Paradoxical activation of oncogenic signaling as a cancer treatment strategy 94%
Similar papers in this journal
- Interrogation of cancer gene dependencies reveals novel paralog interactions of autosome and sexchromosome encoded genes 96%
- NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 95%
Similar papers in this journal
- A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy 96%
- TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function 95%
- Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.